Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details
This article was originally published in The Pink Sheet Daily
Executive Summary
Veteran Merck scientist recruited for personalized-medicine push.
You may also be interested in...
Enzon Hunkers Down, Canceling Spin-Out To Guard Cash
Early-stage pipeline could garner licensing deals as clinical work proceeds, with peak burn year ahead.
Newly Independent Myriad Diagnostics Will Pursue Product Acquisitions
Pharmaceutical group to proceed as an independent developer of cancer, infectious disease therapies.
Abraxis Splits Injectable Generics Business Into Separate Unit
Abraxis CEO says the separation will allow the research business to focus more on personalized medicine.